Switch theme
Sign up to access all valuation multiples
Shandong Weigao Orthopaedic Device Co Ltd is engaged in the research and development, production and sales of orthopedic medical devices.
2005
n/a
LTM Revenue $217M
LTM EBITDA $54.7M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Weigao Group has a last 12-month revenue (LTM) of $217M and a last 12-month EBITDA of $54.7M.
In the most recent fiscal year, Weigao Group achieved revenue of $203M and an EBITDA of $47.0M.
Weigao Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Weigao Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $217M | XXX | $203M | XXX | XXX | XXX |
| Gross Profit | $142M | XXX | $133M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $54.7M | XXX | $47.0M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $42.4M | XXX | $35.6M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $35.5M | XXX | $31.2M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Weigao Group's stock price is CNY 27 (or $4).
Weigao Group has current market cap of CNY 10.7B (or $1.5B), and EV of CNY 8.8B (or $1.2B).
See Weigao Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.5B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Weigao Group has market cap of $1.5B and EV of $1.2B.
Weigao Group's trades at 6.1x EV/Revenue multiple, and 26.2x EV/EBITDA.
Equity research analysts estimate Weigao Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Weigao Group has a P/E ratio of 42.0x.
See valuation multiples for Weigao Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 22.5x | XXX | 26.2x | XXX | XXX | XXX |
| EV/EBIT | 29.1x | XXX | 34.6x | XXX | XXX | XXX |
| EV/Gross Profit | 8.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.0x | XXX | 47.7x | XXX | XXX | XXX |
| EV/FCF | 55.8x | XXX | 35.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWeigao Group's last 12 month revenue growth is 16%
Weigao Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Weigao Group's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Weigao Group's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Weigao Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 52% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Weigao Group acquired XXX companies to date.
Last acquisition by Weigao Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Weigao Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Weigao Group founded? | Weigao Group was founded in 2005. |
| Where is Weigao Group headquartered? | Weigao Group is headquartered in China. |
| Is Weigao Group publicy listed? | Yes, Weigao Group is a public company listed on SHG. |
| What is the stock symbol of Weigao Group? | Weigao Group trades under 688161 ticker. |
| When did Weigao Group go public? | Weigao Group went public in 2021. |
| Who are competitors of Weigao Group? | Similar companies to Weigao Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Weigao Group? | Weigao Group's current market cap is $1.5B |
| What is the current revenue of Weigao Group? | Weigao Group's last 12 months revenue is $217M. |
| What is the current revenue growth of Weigao Group? | Weigao Group revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Weigao Group? | Current revenue multiple of Weigao Group is 5.7x. |
| Is Weigao Group profitable? | Yes, Weigao Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Weigao Group? | Weigao Group's last 12 months EBITDA is $54.7M. |
| What is Weigao Group's EBITDA margin? | Weigao Group's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Weigao Group? | Current EBITDA multiple of Weigao Group is 22.5x. |
| What is the current FCF of Weigao Group? | Weigao Group's last 12 months FCF is $22.1M. |
| What is Weigao Group's FCF margin? | Weigao Group's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Weigao Group? | Current FCF multiple of Weigao Group is 55.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
